IMPORTANCE Although the intent of nephron-sparing surgery is to eradicate malignant tumors found on preoperative imaging, benign masses often cannot be differentiated from malignant tumors. However, in the past there have been discrepancies in the reported percentages of benign masses removed by partial nephrectomy (PNx). 
S mall, localized, incidentally discovered lesions represent the tumors that account for the largest increase in the incidence rate of renal cell carcinoma (RCC) and almost half of the new cases of RCC are localized tumors. 1 It is thought that increasing use of imaging modalities is responsible for the increased incidence of these incidentalomas. 1 Considering the increasingly well-understood disadvantages of radical nephrectomy in localized RCC, partial nephrectomy (PNx) is being used more often and the indications for its use are expanding. American and European guidelines recommend nephron-sparing surgery as the standard of care for patients with T1 masses that can feasibly undergo resection.
2
The receipt of PNx is rising, while that of radical nephrectomy is declining [3] [4] [5] and the increasing use of PNx has yielded a variable frequency of benign pathologic findings, ranging from 8.1% to 27.5%. 6, 7 To date, only a few studies have attempted to investigate the prevalence of benign pathologic findings after PNx and possible risk factors associated with predicting benign pathologic findings after PNx. 8, 9 Moreover, no nationally representative study has investigated the overall prevalence of benign pathologic findings after PNx and its association with radiologic imaging patterns. The aim of this study was to investigate the prevalence of benign pathologic findings after PNx and its association with preoperative imaging patterns using a nationally representative database.
Methods

Data Source
Data were derived from the nationally representative Truven Health Analytics MarketScan Commercial Claims and Encounters and Medicare Supplemental Databases (Truven Health Analytics. MarketScan Research. https://marketscan.truvenhealth. com/marketscanportal/). The data conformed to the Health Insurance Portability and Accountability Act of 1996 confidentiality requirements. Truven Health MarketScan Research Databases includes a database containing individual-level inpatient and outpatient insurance billing claims, which enables longitudinal tracking of patients regardless of different sites of care and multiple treatment years, as well as information regarding inpatient and outpatient treatment, demographic data, diagnoses, procedures, and costs. The use of this database without informed consent of the patients was approved by institutional review board of Stanford University because all data were deidentified.
Study Population
All adults aged 18 years or older with a primary procedure code (using the 
Main Outcome Measures
Our study included 2 main outcomes: overall prevalence of benign pathologic findings after PNx during the study period and the annual trend of benign pathologic findings after PNx. Prevalence was defined as the proportion of patients with a benign pathologic diagnosis among the total patients with PNx. Annual prevalence was defined by proportion of patient number of each year with a benign pathologic diagnosis among total patients with PNx in each year. Secondary outcomes were factors affecting the prediction of the benign pathologic findings after PNx including performance of each imaging modality, pattern of imaging combinations, sex, age, and geographical region. Performance of each imaging modality was defined as any CT (those patients with performance of CT regardless of any other imaging modalities), any MRI, any USG, and any biopsy. The pattern of imaging combination was categorized as CT only, CT and USG, CT and MRI, CT and MRI plus USG, and other combinations (MRI only, MRI and USG, any other combination with biopsy). The date of surgery was set as the index date and preoperative imaging up to 1 year prior to the sur-
Key Points
Question How high is the prevalence of benign pathologic findings after partial nephrectomy, and which radiologic modalities are associated with benign findings after partial nephrectomy?
Findings In this cohort study that included 18 060 patients between 2007 and 2014, overall prevalence of benign pathologic findings after partial nephrectomy was 30.9%, and it was affected by several factors including female sex, old age, and performance of computed tomographic imaging only as preoperative imaging modality.
Meaning
The prevalence of benign pathologic findings after partial nephrectomy is high, and to avoid unnecessary surgeries for renal mass, clinicians have to focus more on possible risk factors, especially radiologic modalities.
gery date was regarded as preoperative imaging for PNx. Additional outcomes included cost analysis regarding surgery, cost by person, and average total cost within 90 days after surgery by person. Cost estimation was as follows: total gross payment to a clinician for a specific service; ie, the amount eligible for payment after applying pricing guidelines such as fee schedules and discounts, and before applying deductibles, copayments, and coordination of benefits. Another additional analysis included prevalence of benign pathologic diagnosis and malignant disease after PNx according to age (>65 years).
Statistical Analyses
Aχ 2 test was conducted to investigate the overall and annual prevalence rate of benign pathologic diagnosis after PNx, and also to compare the difference of performance of imaging patterns during univariate analysis. Post hoc subgroup analysis was performed according to age groups. Multiple logistic regression analyses were undertaken to investigate the significant factors predicting benign pathologic findings. During multiple logistic regression analyses the variable performance of each imaging pattern was not included owing to multicollinearity. All analyses were performed with SAS statistical software (version 9.3; SAS Institute, Inc).
Results
Study Population
A total of 21 445 patients with ICD-9-CM code of 55.4 were identified from 2007 to 2015 using the Truven database system. Patients with no records of preoperative imaging within 1 year from index date (n = 1602) and those patients with nonrelevant diagnostic codes (exclusion criteria and patients with no diagnostic code) (n = 567) were excluded. A total of 18 060 patients were selected for final inclusion (eFigure in the Supplement). Among the 18 060 participants, 10 637 (58.9%) were men and 7423 (41.1%) were women. Basic characteristics of the study cohort are described in 
Prevalence of Benign Pathologic Findings After PNx
The crude number of benign pathologic diagnoses was 5588 among the 18 060 patients, and the overall prevalence was 30.9%. The annual prevalence of benign pathologic findings after PNx was lowest in 2007 as 19.9% and was highest in 2010 as 33.52%. The Figure shows the annual prevalence of benign and malignant pathologic diagnoses after PNx. With the exception of 2007, the annual rate of benign pathologic findings exceeded 30%. In additional analyses according to age, overall prevalence of benign pathologic diagnoses among patients younger than 65 and 65 years or older was 29.6% and 35.9%, respectively ( Table 2) . In both age groups, the prevalence rate showed an increasing pattern until 2012, with a slightly decreased pattern thereafter. Average annual percentage change (AAPC) was estimated to be 4.0% by methodology of NIH and approximately 4.0% to 6.85% by log-adjusted modelling. Table 3 summarizes the univariate analysis of imaging patterns including imaging performance and imaging combination types. Performance of MRI and biopsy was significantly associated with higher rates of malignant pathologic diagnoses (P = .02 and P < .001, respectively). 
Prediction of Benign or Malignant Pathologic Findings After PNx
Cost Analysis
The cost analysis included surgery cost and total cost within 90 days after surgery by person and are summarized in Table 1 
Discussion
To our knowledge, this is the first nationally representative study to report the most recent prevalence of benign pathologic diagnosis after PNx and its association with preoperative imaging patterns. The prevalence of benign pathologic findings after PNx routinely exceeded 30% and performance of MRI or biopsy before surgery could provide a better prediction of true malignant abnormalities.
As the proportion of PNx compared with radical nephrectomy continues to increase, 4 most of the research has focused on expansion of indications of PNx, even with clinical stage 3 lesions, with sinus fat invasion 10,11 and on complications including ischemia time and blood loss, and CKD. 12 To date, only a few reports have focused on the benign pathologic findings after PNx 8,9,13,14 and the prevalence of benign pathologic diagnoses has varied widely from 8% to 30%. Among the studies reporting the prevalence of benign pathologic findings, 6 studies reported a high rate (>25%), similar to our findings. Considering the crucial problem of the socioeconomic burden of PNx and its related complications among patients with benign pathologic findings, it is clear that urologists have to focus on attempting to reduce nonmalignant final pathologic findings. Among the solutions, ascertaining the accuracy of preoperative radiologic imaging modalities is important; however, no study has thus far included the preoperative imaging modalities as a potential factor.
The role of pre-PNx imaging modalities is well established with good accuracy in predicting RCC. [15] [16] [17] [18] However, to date, no studies have addressed the trends of preoperative imaging or in its efficacy in predicting for malignant histologic findings. We found that the combination of MRI and biopsy were associated with a higher rate of malignant pathologic diagnoses, which implies that a multimodality approach may be more accurate. Furthermore, multiple logistic regression analysis showed that imaging combinations were superior to the performance of CT alone to accurately predict malignant pathologic findings. Although CT is still the standard modality to predict a renal mass and still displays a high accuracy rate, 16 for the past decade, other studies have demonstrated that MRI and renal mass biopsy can be highly predictive. 15, [17] [18] [19] However, current imaging modalities are still limited in differentiating benign from malignant lesions, especially in the case of distinguishing oncocytoma or lipid-poor angiomyolipoma from RCC.
20,21
However, the present results are still notable because of the To date, there is no consensus on the utility of pre-PNx imaging other than for CT. Most reports on the accuracy of MRI to predict RCC in small renal masses are based on retrospec- 27 Our study also showed female predominance in benign pathologic findings after PNx. However, with regard to age, the older age group showed higher predominance in benign pathologic findings after PNx.
Reducing the benign pathologic findings after PNx is an important issue considering the inherent surgical risk and surgery-related costs. Given our findings, it may be helpful for urologists to focus more on the extended role of MRI and the performance of biopsy to reduce benign pathologic findings after PNx. Recently, more high-quality evidence of the performance of biopsy in patients with suspicious small renal malignant tumors has been published, [28] [29] [30] which provide further information about the possible final diagnosis in situations with equivocal clinical and radiographic findings.
Limitations
Although this study is the first nationally representative cohort study about the prevalence of benign pathologic findings after PNx, several limitations exist. First, as this is an administrative data set, there is no information about tumor size and pathologic stage. Although this study used diagnosis codes for identification of the cohort and outcomes, there is a possibility of misclassification bias. We could not surmise a reason why there were patients in the database who were excluded because they had no records of pre-PNx imaging. Second, we could not classify the types of surgical approaches including open, laparoscopic, or robotic surgery. Increasing availability of robotic surgery could be an important factor for benign pathologic diagnoses after PNx as well as increased imaging modalities. Moreover, there is a marked difference of the prevalence between 2007 and other years, which could be explained by fast dissemination of robotic assisted PNx. Third, the cost data we used were total payments, which is directly associated with consumers' total expense. However, it is possible that this may not be reflective of the total charge cost, which is related to a variety of charges including the direct and indirect cost of the hospital stay. Although there was a marked difference in the total payment costs between the benign and malignant diagnoses groups, this difference could not be fully explained. It is possible that fixed cost may account for the difference, which is associated with surgical equipment costs and increased operation times. Moreover, there are 2 types of fee paying: fee-for-service and encounter. In addition, immunohistochemical staining cost, oncotyping, additional radiologic imaging before or during the operation after admission could be possible factors for the difference.
Conclusions
Prevalence of benign pathologic findings after PNx is not low, and exceeds 30% on an ongoing annual basis. Each imaging modality including MRI and biopsy, and combinations of modalities affect the prediction of benign pathologc findings.
Urologists have to focus more on high prevalence of benign pathologic findings after PNx and consider other imaging modalities including MRI and biopsy. Avoiding unnecessary surgery is more than an issue of cost-effectiveness in patients' view. Clinicians have to focus more to make every effort to reduce the likeleyhood of benign pathologic findings after PNx.
